Cancer drug success sends this company soaring 🎉

Check out this game-changer and other movers                                                                                                                                                                                                                                                                                                                                                                                                                 Good morning, 360! Here are our top investing ideas today – and U.S. stock futures edged upward ahead of today's open as we prepare for the Fed’s announcement of another increase in interest rates...stay tuned and hold on to your seats! IMGN - Up over in 100% in pre-market after Phase 3 success in ovarian cancer trial GDC - Up over 40% after pricing downsized stock offering SMCI - 9% higher after increased earnings guidance *A Message on Behalf of Metals Research Report 🔥 Hot Stock of the Day 🔥 Graphite One, Inc (Ticker: GPHOF) We don’t normally look at stocks with “5 letter tickers,” but for today’s idea, we had to cross the border and look at a Canadian company that also trades in the U.S. Why? Because graphite is such a [critical component of rechargeable batteries](, and there just aren’t any stocks we like in that sector that are U.S.-based. Elon Musk even recently said that this is a “paramount concern.” GPHOF is one of the few companies out there that is trying to solve this problem with [domestically-produced resources](. In fact, the governor of Alaska [said](, “Graphite Creek is the largest deposit of graphite in the Nation, and would be a superior domestic supply of this critical mineral, which is necessary for modern batteries, renewable energy technology, and many other high-tech uses.” Best of all, this tiny $1 stock is poised for something BIG. You really need to make sure GPHOF is on your radar right now. Do yourself a favor and get started on your research by [reading the report our friends at Metals Research]( have put together. *Sponsored by Lifewater Media. Please see disclosures below. IMGN - Up over in 100% in pre-market after Phase 3 success in ovarian cancer trial ImmunoGen (IMGN) announced this morning that its drug ELAHERE demonstrated overall survival benefit in its Phase 3 MIRASOL Trial in patients with FRa-Positive platinum-resistant ovarian cancer. Here are some [recent headlines](: Results Show Statistically Significant Improvements in PFS, ORR, and OS Compared to Chemotherapy First Medicine to Demonstrate an Overall Survival Advantage in Platinum-Resistant Ovarian Cancer Submission of MAA in Europe and sBLA in US Anticipated in H2 2023 Further, [Kathleen Moore](, Associate Director of Clinical Research and Director of the Oklahoma TSET/Sarah Cannon Phase I Program stated, "I believe the data from the confirmatory MIRASOL trial are practice-changing. They demonstrate ELAHERE's superiority to chemotherapy based on all efficacy endpoints, in particular overall survival, and build on the clinical benefit of ELAHERE previously reported in the SORAYA trial.” The $10 area acted as resistance in the pre-market and now becomes a potential support area. Above it, targets to the upside are $10.80, $12 and then the pre-market high of $12.19. Beyond that, targets are $13, $14, and $15 with the 10-year high around $20. Below $10, there is potential support at $9.20, $9, $8, $7.70 and then $6.50. GDC - Up over 40% after pricing downsized stock offering GD Culture Group (GDC) - a company that focuses on research, development, and application of Internet of Things (IoT) and electronic token digital door signs to its customers in China (through its subsidiaries) - priced its downsized stock offering to $9.55 million from $11.55 million priced at the market with warrants at $8.27 per share. The stock closed down 89% yesterday after the offering was announced and is 40% higher this morning after the downsize. The $4.60 area has acted as support so far in the pre-market and will be an important level to watch. Above it, targets to the upside are at $5, $5.70, $6 and then $6.20. Beyond that targets are at $6.80, $8 and $10. Below $4.60 there is potential support at $4.40, $4.20 and a gap to fill at $3.40. SMCI - 9% higher after increased earnings guidance. Super Micro Computer (SMCI) - a global leader in high-performance, high-efficiency server technology, and innovation - is 9% higher in pre-market after increasing its guidance for next quarter and more important for the full year after missing analyst estimates last quarter. SMCI reported Q3 EPS of $1.63, $0.36 worse than the analyst estimate of $1.99. Revenue for the quarter came in at $1.28 billion versus the consensus estimate of $1.46 billion. SMCI guided Q4 2023 EPS of $2.21-$2.71, versus the consensus of $1.76 with Q4 2023 revenue of $1.7-1.9 billion, versus the consensus of $1.675 billion. SMCI sees FY2023 EPS of $10.50-$11.00, versus the consensus of $10.13 with FY2023 revenue of $6.6-6.8 billion, versus the consensus of $6.686 billion. $113 has acted as support in the after-hours yesterday and the pre-market this morning, and will be an important level to watch. Above it, targets to the upside are at $114.50 and the pre-market high $115.50. Beyond that, targets are at $116.50, $117 and then the all-time high at $119.24. Below $113, there is potential support at $112, $110, $108 and a gap to fill at $104.43. Economic Calendar (EST) 7:00am MBA Mortgage Applications 8:15 am ADP employment report 8:30 am Treasury refunding. 9:45 am PMI Composite Final 10:00 am ISM Services Index 10:30am EIA Petroleum Report Fed Speakers scheduled. 2:00 pm FOMC announcement 2:30 pm Fed Chair Jerome Powell Earnings for Today (After Market) ACEL, ACLS, ACR, ACT, ADPT, AEIS, ALB, ALKT, ALL, ALLO, AMED, AMK, AMOT, AMPY, AMWL, ANSS, APA, ARC, ARDX, ASPN, ATO, ATUS, AUR, AVNW, AVT, BBSI, BCOV, BHE, BKH, BNL, CCRN, CDAY, CENT, CFLT, CHRD, CIVI, CLMB, CMPO, CODI, COKE, CORT, CPE, CPK, CPS CSGS, CSTL, CSV, CTSH, CTVA, CW, CXW, DEN, DHT, DLHC, DRS, ECOR, ECPG, EQC, EQH, EQIX, ERII, ES, ESTE, ETSY, EVH, FARO, FATE, FBRT, FG, FLT, FNF, FORM, FPI, FROG, FSLY, GHL, GIL, GKOS, GL, GMRE, GNK, GNW, GOOD, GRBK, GTBIF, HBB, HCC, HDSN, HOUS, HST, HUBS, INFA, INFN, INMB, INN, INSG, IOSP, IPI, IR, IVAC, JOBY, KLIC, KNTK, KTOS, KW, LESL, LMND, LUMO, MELI, MET, METC, MG, MGY, MKSI, MLR, MMS, MOR, MOS, MRAM, MRO, MTG, MX, MYGN, NARI, NC, NE, NFG, NGVT, NSTG, NUS, NVEC, NVST, NWPX, NYMT, O, OLED, OM, OPAD, OPK, OUT, PAHC, PARR, PCOR, PDCE, PGRE, PKOH, PLMR, PSA, PSNL, QCOM, QDEL, QGEN, QNST, QRVO, RDN, RELY, REZI, RGLD, RGNX, RGR, RHP, RM, RMNI, RMR, ROOT, RPT, RSI, RUN, RVLV, RYN, SBOW, SBRA, SEDG, SIGI, SITM, SNEX, SP, SPNT, SPOK, SRC, SRI, SRTS, STAA, SUM, SYNA, TIPT, TNDM, TPIC, TPL, TPVG, TRIP, TTEC, TTMI, TWI, TXG, UDMY, UFI, UGI, ULCC, UPWK, USDP, USIO, USPH, VAC, VAPO, VET, VMEO, VNDA, VSTO, VTOL, WEAV, WERN, WES, WMB, WTS, YELL, Z, ZG, ZIMV Top Headlines SANA Sana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting SGMO: Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) MUSA Murphy USA Inc. Announces $1.5 Billion Repurchase Program THC Tenet Announces Pricing of its $1.350 Billion Private Offering of Senior Secured Notes MRNA Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines FFIE Faraday Future Confirms Receipt of an Additional 180-day Extension From NASDAQ to Meet NASDAQ Minimum Bid Price Requirement PFE Pfizer Intends To Start Selling Haleon Stake Within Months, Says CFO – FT CLEU China Liberal Education Holdings Limited Announces the Termination of Merger Agreement with AIWAYS Holdings Limited F Ford CFO Sees Cost Cuts Of $2Bln This Year, Shy Of $2.5Bln Goal - Commodity Costs Not Coming Down As Quickly As Expected WPRT Westport Showcases its Market Ready HPDI™ Fuel System, A Single Solution for Multiple Fuels at ACT Expo 2023 PERI Perion’s Momentum Continues, Delivering 16% Revenue Growth and 54% Increase in Net Income MLTX: MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply OCN FOA: PHH Mortgage Announces New Subservicing Agreement with Finance of America Reverse EL: Lowering Full-Year Outlook to Reflect More Gradual Recovery in Asia Travel Retail BMY: Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy LH: LABCORP AND JEFFERSON HEALTH ANNOUNCE STRATEGIC LABORATORY RELATIONSHIP SPWR: SunPower Secures $550M Loan Purchase Commitment From KKR DXCM Dexcom Prices Upsized Offering of $1.1 Billion of 0.375% Convertible Senior Notes Due 2028 MGTA: Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement GOGO: Gogo Announces First Quarter Results and Pays Down $100 Million of Debt, Reiterates 2023 Guidance and Long-Term Targets KMDA: Kamada Announces U.S. FDA Approval of its Application to Manufacture CYTOGAM® at the Company’s Facility in Israel AKLI: Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic AKTS: Akoustis Receives First Wi-Fi 7 Design Win from Leading Enterprise-Class Customer INVE: Identiv Makes Intelligent, Integrated Video Surveillance and Access Control Easy to Adopt and Manage with the Velocity Vision Ecosystem CYN: AI-Powered Autonomous Industrial Vehicles at the Push of a Button: Cyngn Releases Enterprise Autonomy Suite 9.0 CSTL: Study Demonstrates Use of DecisionDx®-Melanoma to Guide Treatment Decisions Resulted in Earlier Detection of Melanoma with Decreased Metastatic Tumor Burden Compared to Patients Without Surveillance Imaging Studies KHC -- Continues to anticipate high single digit inflation this year MNTS Momentus Signs Contract to Carry Hosted Payload for Hello Space To Your Success! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull - Refund Policy - Privacy Policy - Terms & Conditions *PAID ADVERTISEMENT. RagingBull has been paid fourteen thousand dollars by ach bank transfer by Lifewater Media for advertising Graphite One, Inc. from a period beginning on May 3, 2023 through May 4 of the same year. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of Raging Bull, do not hold a position in Graphite One, Inc. This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Graphite One, Inc., increased trading volume, and possibly an increased share price of the Graphite One, Inc. securities, which may or may not be temporary and decrease once the marketing arrangement has ended. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull can guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https:// www. sec. gov/edgar /searchedgar/companysearch TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. [tw]( Update your email preferences or unsubscribe [here]( © 360wallstreet 62 Calef Hwy. #233 Lee, NH 03861, United States [[beehiiv logo]Powered by beehiiv](